These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging. Chen J; Xia C; Duan T; Cao L; Jiang H; Liu X; Zhang Z; Ye Z; Wu Z; Gao R; Shi Y; Song B Eur Radiol; 2021 Oct; 31(10):7696-7704. PubMed ID: 33856520 [TBL] [Abstract][Full Text] [Related]
5. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. Liang Y; Xu F; Wang Z; Tan C; Zhang N; Wei X; Jiang X; Wu H Eur J Radiol; 2022 Aug; 153():110356. PubMed ID: 35623312 [TBL] [Abstract][Full Text] [Related]
6. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. Rhee H; Cho ES; Nahm JH; Jang M; Chung YE; Baek SE; Lee S; Kim MJ; Park MS; Han DH; Choi JY; Park YN J Hepatol; 2021 Jan; 74(1):109-121. PubMed ID: 32818570 [TBL] [Abstract][Full Text] [Related]
7. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI. Cha H; Choi JY; Park YN; Han K; Jang M; Kim MJ; Park MS; Rhee H Eur Radiol; 2023 Feb; 33(2):1364-1377. PubMed ID: 35999373 [TBL] [Abstract][Full Text] [Related]
8. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma based on B-Mode US and CEUS. Luo M; Liu X; Yong J; Ou B; Xu X; Zhao X; Liang M; Zhao Z; Ruan J; Luo B Eur Radiol; 2023 Jun; 33(6):4024-4033. PubMed ID: 36484835 [TBL] [Abstract][Full Text] [Related]
9. Steatotic hepatocellular carcinoma: Association of MRI findings to underlying liver disease and clinicopathological characteristics. Park JH; Park YN; Kim MJ; Park MS; Choi JY; Chung YE; Rhee H Liver Int; 2023 Jun; 43(6):1332-1344. PubMed ID: 37088983 [TBL] [Abstract][Full Text] [Related]
10. A radiomics nomogram based on contrast-enhanced MRI for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. Zhu Y; Weng S; Li Y; Yan C; Ye R; Wen L; Zhou L; Gao L Abdom Radiol (NY); 2021 Jul; 46(7):3139-3148. PubMed ID: 33641018 [TBL] [Abstract][Full Text] [Related]
11. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Kang HJ; Kim H; Lee DH; Hur BY; Hwang YJ; Suh KS; Han JK Radiology; 2021 Sep; 300(3):572-582. PubMed ID: 34227881 [TBL] [Abstract][Full Text] [Related]
12. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R; Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447 [TBL] [Abstract][Full Text] [Related]
13. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Zheng W; Huang H; She D; Xiong M; Chen X; Lin X; Cao D Abdom Radiol (NY); 2022 Mar; 47(3):957-968. PubMed ID: 34964069 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085 [TBL] [Abstract][Full Text] [Related]
15. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma? Wei H; Jiang H; Liu X; Qin Y; Zheng T; Liu S; Zhang X; Song B Eur J Radiol; 2020 Nov; 132():109312. PubMed ID: 33022551 [TBL] [Abstract][Full Text] [Related]
16. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Yoon JK; Choi JY; Rhee H; Park YN Eur Radiol; 2022 Aug; 32(8):5119-5133. PubMed ID: 35258675 [TBL] [Abstract][Full Text] [Related]
17. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947 [TBL] [Abstract][Full Text] [Related]
18. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease. Lee SE; An C; Hwang SH; Choi JY; Han K; Kim MJ Eur Radiol; 2018 Apr; 28(4):1551-1559. PubMed ID: 29134355 [TBL] [Abstract][Full Text] [Related]
19. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. Jeon SK; Joo I; Bae JS; Park SJ; Lee JM Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875 [TBL] [Abstract][Full Text] [Related]
20. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI. Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]